A A A

You are here: Funding Results / Recent competition results / Results of the 2016 Breast Cancer Research Grants Program competition

Results of the 2016 Breast Cancer Research Grants Program competition

On February 1, 2017, the Canadian Breast Cancer Foundation (CBCF) and the Canadian Cancer Society (CCS) joined forces to become one organization – the Canadian Cancer Society. As a result, CBCF’s grant programs have merged into the Canadian Cancer Society's research portfolio, and will adhere to CCS research policies and procedures moving forward.

We are pleased to announce the results of the Canadian Cancer Society Breast Cancer Research Grants Program (formerly the CBCF National Research Grant Program). The goal of this program is to support breast cancer research in Canada that demonstrates scientific excellence, relevance, and innovation and that has the potential to achieve a significant impact on breast cancer. Below is a listing of newly awarded CCS Breast Cancer Research Grants.

14 Breast Cancer Research Grants have been approved – 21% of full proposals received. One-hundred eighty-three LOIs were submitted for review, and following scientific review 72 of these were invited to submit a Full Application and 67 were received. Grants are valued at up to $450,000 over a 3-year term. These 14 new grants represent an investment of almost $5.9 million.

Funds committed to this competition have been made possible by the significant efforts of donors and volunteers across the country, and particularly the CIBC Run for the Cure.

Summaries of awarded grants

Please note: 

  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
  • The start date for these grants is July 1, 2017.
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.


Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Applicant
Institution
Title		 Award
Cescon, David
University Health Network
Novel cell-free DNA assays to predict relapse and guide systemic therapy in early breast cancer 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $150,000
Davey, Scott
Queen's University
A functional approach to assessing variants of unknown significance in BRCA1 carriers 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $150,000
Godbout, Roseline
University of Alberta
Targeting p53-mutated triple-negative breast cancer: role of nuclear factor IB 		2017/2018 :  $149,920
2018/2019 :  $149,920
2019/2020 :  $149,920
Gunning, Patrick
University of Toronto
Small molecules targeting aberrant STAT3 activity in breast cancer: killing breast tumour cells and inducing anti-tumour immune response 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $150,000
Johnston, Brent
Dalhousie University
Targeting breast cancer via combined natural killer T cell immunotherapy and oncolytic virotherapy 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $150,000
Khokha, Rama
University Health Network
Rationalized depletion of mammary progenitors as a program for breast cancer prevention 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $150,000
Kotsopoulos, Joanne
Women's College Hospital
Delineating a role of RANKL/OPG-signalling on breast cancer development 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $149,650
Lee, Jonathan
University of Ottawa
Control of breast cancer by cooperation between the PI4KIIIB lipid kinase and the Rab11a GTPase 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $149,919
Lohrisch, Caroline
BC Cancer Agency
LA LEAST. Luminal A, Limited Endocrine Adjuvant Systemic Therapy, a phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2 negative early breast cancer 		2017/2018 :  $150,000
2018/2019 :  $150,000
2019/2020 :  $150,000
Metcalfe, Kelly
University of Toronto
Breast cancer treatment in women with PALB2 mutations 		2017/2018 :  $149,071
2018/2019 :  $146,637
2019/2020 :  $149,481
Nielsen, Torsten
Vancouver General Hospital
Clinical utility of immune response biomarkers for aggressive breast cancers 		2017/2018 :  $149,343
2018/2019 :  $149,848
2019/2020 :  $149,446
Ross, Colin
University of British Columbia
Pharmacogenomic discovery of predictive cardiotoxicity biomarkers in breast cancer patients receiving anthracycline chemotherapies 		2017/2018 :  $148,942
2018/2019 :  $147,353
2019/2020 :  $148,230
Shepherd, Lois
Queen's University
Quantitative standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) for prognostic and/or predictive index for response to adjuvant aromatase inhibitors exemestane or anastrozole 		2017/2018 :  $59,300
2018/2019 :  $80,111
2019/2020 :  $5,000
Whelan, Timothy
McMaster University
Prospective cohort study evaluating risk of local recurrence following breast conserving surgery alone in low risk luminal A breast cancer 		2017/2018 :  $115,183
2018/2019 :  $101,272
2019/2020 :  $118,391

Last modified on: December 2, 2019